



May 30, 2022

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides receives USFDA approval for Ibuprofen Oral Suspension”**

Thanks & Regards,  
For **Strides Pharma Science Limited,**

A handwritten signature in blue ink that reads 'Manjula R.'.

**Manjula Ramamurthy**  
**Company Secretary**



Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700  
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

---

## Strides receives USFDA approval for Ibuprofen Oral Suspension

*To be marketed by Strides Pharma Inc. in the US market*

---

**Bengaluru, May 30, 2022** – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for **Ibuprofen Oral Suspension USP, 100 mg/5 mL** from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil).

According to IQVIA MAT March 2022 data, the US market for Ibuprofen Oral Suspension USP, 100 mg/5 mL is approximately ~US\$ 66 Mn. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 274 cumulative ANDA filings (including recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 250 ANDAs have been approved and 24 are pending approval. The company currently has ~60 commercialized products in the US and has set a target to launch ~ 20 new products every year from the combined portfolio.

### About Ibuprofen Oral Suspension USP

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain from various conditions such as headache, dental pain, menstrual cramps, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu.

### About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (New York). The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com)

### For further information, please contact:

#### Strides

##### **Badree Komandur**

Executive Director - Finance & Group CFO  
+91 80 6784 0747

#### Investor Relations:

**Sandeep Baid:** +91 80 6784 0791

Email: [Sandeep.baid@strides.com](mailto:Sandeep.baid@strides.com)

#### Corporate Communication

**Pallavi Panchmatia:** +91 80 6784 0193

[pallavi.panchmatia@strides.com](mailto:pallavi.panchmatia@strides.com)

#### PR Consultancy

Fortuna PR

**K Srinivas Reddy:** +91 90005 27213

[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,  
Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560 076

Boni Mukherjee: +91 96186 82208

[boni@fortunapr.com](mailto:boni@fortunapr.com)